MX2020005930A - Forma cristalina del inhibidor del canal medular renal externo de potasio y metodo de preparacion del mismo. - Google Patents

Forma cristalina del inhibidor del canal medular renal externo de potasio y metodo de preparacion del mismo.

Info

Publication number
MX2020005930A
MX2020005930A MX2020005930A MX2020005930A MX2020005930A MX 2020005930 A MX2020005930 A MX 2020005930A MX 2020005930 A MX2020005930 A MX 2020005930A MX 2020005930 A MX2020005930 A MX 2020005930A MX 2020005930 A MX2020005930 A MX 2020005930A
Authority
MX
Mexico
Prior art keywords
crystal form
preparation
potassium channel
outer medullary
renal outer
Prior art date
Application number
MX2020005930A
Other languages
English (en)
Inventor
Guaili Wu
Yun Lu
Quanliang Zhang
Fei Yao
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2020005930A publication Critical patent/MX2020005930A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion proporciona una forma cristalina de un inhibidor del canal medular renal externo de potasio y un metodo de preparacion del mismo; en particular, la presente invencion proporciona la forma cristalina III de un L-tartrato de un inhibidor del canal medular renal externo de potasio (ROMK) y un metodo de preparacion del mismo; la forma cristalina III tiene buena estabilidad quimica y estabilidad de la forma cristalina y el solvente de cristalizacion utilizado tiene baja toxicidad y residuo; de este modo, la presente invencion se puede utilizar mejor en tratamiento clinico.
MX2020005930A 2017-12-06 2018-12-05 Forma cristalina del inhibidor del canal medular renal externo de potasio y metodo de preparacion del mismo. MX2020005930A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201711273099 2017-12-06
PCT/CN2018/119310 WO2019109935A1 (zh) 2017-12-06 2018-12-05 一种肾外髓质分泌钾通道抑制剂的晶型及其制备方法

Publications (1)

Publication Number Publication Date
MX2020005930A true MX2020005930A (es) 2020-08-24

Family

ID=66750805

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005930A MX2020005930A (es) 2017-12-06 2018-12-05 Forma cristalina del inhibidor del canal medular renal externo de potasio y metodo de preparacion del mismo.

Country Status (13)

Country Link
US (1) US20200347039A1 (es)
EP (1) EP3722293A4 (es)
JP (1) JP2021505602A (es)
KR (1) KR20200096802A (es)
CN (1) CN111372929B (es)
AU (1) AU2018380171A1 (es)
BR (1) BR112020011161A2 (es)
CA (1) CA3084848A1 (es)
MX (1) MX2020005930A (es)
RU (1) RU2020122014A (es)
TW (1) TWI685492B (es)
WO (1) WO2019109935A1 (es)
ZA (1) ZA202004017B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673920B2 (en) * 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
AR092031A1 (es) * 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
US9777002B2 (en) * 2012-11-29 2017-10-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
JP6736816B2 (ja) * 2014-12-08 2020-08-05 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ピリジンカルボキサミド誘導体、それらの製造方法およびそれらの医薬用途
TW201742866A (zh) * 2016-06-07 2017-12-16 江蘇恆瑞醫藥股份有限公司 一種腎外髓質分泌鉀通道抑制劑的可藥用鹽
CN109879863B (zh) * 2017-12-06 2020-10-20 江苏恒瑞医药股份有限公司 一种肾外髓质分泌钾通道抑制剂的晶型及其制备方法

Also Published As

Publication number Publication date
BR112020011161A2 (pt) 2020-11-17
CN111372929B (zh) 2022-04-12
CN111372929A (zh) 2020-07-03
WO2019109935A1 (zh) 2019-06-13
US20200347039A1 (en) 2020-11-05
EP3722293A4 (en) 2021-06-02
EP3722293A1 (en) 2020-10-14
TW201925191A (zh) 2019-07-01
ZA202004017B (en) 2021-08-25
RU2020122014A (ru) 2022-01-10
KR20200096802A (ko) 2020-08-13
CA3084848A1 (en) 2019-06-13
TWI685492B (zh) 2020-02-21
JP2021505602A (ja) 2021-02-18
AU2018380171A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2017008520A (es) Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
MD4650B1 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
DK3341355T3 (da) (s)-3-amino-4-(difluormethylenyl)cyclopent-1-en-1-carboxylsyre og tilhørende forbindelser som gaba-aminotransferaseinaktivatorer til behandling af epilepsi, afhængighed og hepatocellulært karcinom
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
SG10201806020VA (en) Electroactive bioadhesive compositions
TW201625535A (en) Inhibitors of histone demethylases
MY173400A (en) Acid composition based on leonardite and amino acids
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
PH12020550556A1 (en) Novel combinations of defoliants
WO2015123449A3 (en) Compositions and methods of using microrna inhibitors
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
LT2015044A (lt) Sijos komponentai, skirti techniniam konstravimui, konstravimo rinkinys ir sijos komponentų sujungimo būdas
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
DOP2017000085A (es) Derivados estabilizados de adrenomedulina y uso de los mismos
MX2017011392A (es) P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su metodo de preparacion.
WO2018189661A3 (en) Methods and compounds for treating diabetes
MX2016003725A (es) Compuestos y su uso para la preparacion de agentes de formacion de imagen tau y formulaciones para la formacion de imagen tau.